Spots Global Cancer Trial Database for Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head
Official Title: Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head
Study ID: NCT00204542
Conditions
Study Description
Brief Summary: Topical treatment of mild to moderate actinic keratosis located on the face and head with Solaraze® is known to be a safe and efficient treatment option. However, it is unclear if an expansion of the treatment period to 6 months will increase the rate of complete responses. Therefore the investigators will evaluate the efficacy and safety of the treatment of actinic keratosis with Solaraze® applied twice daily to the face and head over 3 or 6 months of treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8, Tübingen, BW, Germany
Klinik fuer Dermatologie, Venerologie und Allergologie der Charite, Berlin, , Germany
Dept. of Dermatology, Freiburg, , Germany
Praxis Priv.-Doz. Dr. med. Dirschka, Wuppertal, , Germany
Contact Details
Name: Claus Garbe, MD
Affiliation: Skin Cancer Program, Department of Dermatology, University Hospital Tübingen
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
